Leandro Jonata de Carvalho Oliveira

11PUBLICATIONS
55CO-AUTHORS
Predictive and prognostic markersCancer geneticsMolecular targetsNanotoxicology, health and safetySolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Mar 06, 2026
Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520).

Leandro Jonata de Carvalho Oliveira, Daniella Castro Araújo, Júlio Antonio Pereira de Araújo

|Jan 30, 2026
Cost-Effectiveness of the Oncotype DX Breast Recurrence Score Test in the Brazilian Private Health Care Sector.

Ivan Zimmermann, Carlos Alberto da Silva Magliano, Leandro Jonata de Carvalho Oliveira

|Oct 22, 2025
Budget Impact of the Oncotype DX Test in Early-Stage Breast Cancer for the Brazilian Private Health Care System.

Carlos Alberto da Silva Magliano, Ivan R Zimmermann, Leandro Jonata de Carvalho Oliveira

|Jul 14, 2025
Understanding and overcoming CDK4/6 inhibitor resistance in HR+/HER2- metastatic breast cancer: clinical and molecular perspectives.

Jessé Lopes da Silva, Leandro Jonata de Carvalho Oliveira, Cristiano Augusto Andrade de Resende

|May 24, 2023
Results of a survey study on health professionals' perceptions of tumor boards in Brazil.

Thamirys U Menezes, Márcia Mp Serra, Carlos He Barrios

|Jan 05, 2023
Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study.

Leandro Jonata Carvalho Oliveira, Thais Baccili Cury Megid, Daniela Dornelles Rosa

Pageof 2

Frequent Collaborators

7 joint publications

Max Senna Mano

4 joint publications

Tomás Reinert

3 joint publications

Daniele Assad-Suzuki

3 joint publications

Carlos Henrique Dos Anjos